Gilead Sciences, INC

Gilead Sciences, Inc. announced the pricing of a $3 billion senior notes offering across four tranches with maturities ranging from 2028 to 2034.

Gilead Sciences reported first quarter 2026 results with total revenues up 4% to $7.0 billion, driven by strong performance in its base business, particularly HIV products, and raised full-year revenue guidance.

Gilead Sciences held its 2026 annual meeting, re-electing nine directors and approving an amended equity incentive plan, while rejecting several stockholder proposals.

Gilead Sciences has finalized its acquisition of Arcellx, Inc., for approximately $7.8 billion, gaining full control of the investigational CAR T-cell therapy anito-cel for multiple myeloma.

Gilead Sciences announced a definitive agreement to acquire Arcellx for an implied equity value of $7.8 billion, gaining full control of the promising BCMA-directed CAR T-cell therapy anito-cel for multiple myeloma.

Gilead Sciences announced robust fourth quarter and full year 2025 financial results, driven by HIV and Liver Disease product growth, and provided optimistic 2026 guidance.

Gilead Sciences reports Q1 2026 revenue of $6.96 billion and announces significant strategic acquisitions in oncology and immunology.

Gilead Sciences reported a significant increase in net income and diluted EPS for Q3 and the first nine months of 2025, driven by a $400 million intellectual property sale and substantially lower impairment charges compared to the prior year.

Gilead Sciences reported a 2% increase in total revenues for Q2 2025, driven by strong HIV product sales, while navigating pipeline impairments and ongoing legal challenges.

Gilead Sciences' Q1 2025 results show stable revenue driven by HIV product sales, offsetting declines in Veklury and Oncology, with a net income rebound compared to a loss in the previous year.

Gilead Sciences' Q3 2024 results show a net loss driven by significant R&D impairments, despite a revenue increase.

Gilead Sciences' second-quarter results show a revenue increase but a net loss due to significant R&D expenses and impairments.

Gilead Sciences, Inc. reported a 2% increase in total revenues to $29.4 billion in 2025, driven by robust HIV product sales and significant R&D pipeline advancements, despite challenges in Veklury and Cell Therapy sales.

Gilead Sciences' 2024 results show revenue growth driven by HIV and oncology, but net income was significantly impacted by Trodelvy impairment charges and increased R&D expenses.

Gilead Sciences' 2023 annual report reveals a slight revenue decrease offset by growth in HIV and oncology, alongside significant R&D investments and strategic collaborations.

Andrew D Dickinson, Chief Financial Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock on July 15, 2026 for $129.93 per share.

Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock on July 15, 2026 for $129.92 per share.

Gilead Sciences Chairman & CEO Daniel O'Day reported the sale of company stock under a pre-arranged trading plan.

Gilead Sciences Chief Commercial & Corporate Affairs Officer Johanna Mercier sold 3,000 shares of common stock via a 10b5-1 plan.

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Chief Medical Officer Dietmar Berger acquired 533 shares of Gilead Sciences common stock through the vesting of restricted stock units.

Gilead Sciences has scheduled its 2025 Annual Meeting for May 7, 2025, and is soliciting shareholder votes on director elections, auditor ratification, executive compensation, and several stockholder proposals.

Gilead Sciences is focusing on innovation in virology, oncology, and inflammation to drive long-term growth, highlighted by the potential FDA approval of lenacapavir, a twice-yearly injection for HIV prevention.

Gilead Sciences has scheduled its 2024 Annual Meeting for May 8, 2024, and is seeking shareholder votes on director elections, auditor ratification, executive compensation, and several other proposals.

Gilead Sciences outlines its strategic priorities, including bringing 10+ transformative therapies to patients by 2030 and maximizing near-term revenue growth, in its 2024 Proxy Statement.

Gilead Sciences, Inc. reported 5 holdings worth $1.6B for the period ended June 30, 2026.

Gilead Sciences reports $2.12 billion in equity holdings across six biotechnology investments as of March 31, 2026.

Gilead Sciences, Inc. filed its Form 13F-HR, revealing $1.94 billion in equity holdings across six biotechnology companies as of December 31, 2025.

Gilead Sciences, Inc. reported its institutional equity holdings for the quarter ended September 30, 2025, totaling $1.79 billion across nine positions.

Gilead Sciences, Inc. filed its Q2 2025 Form 13F-HR, revealing over $1.28 billion in equity holdings across 14 biopharmaceutical companies.

Gilead Sciences, Inc. discloses its holdings as of March 31, 2025, showcasing significant investments in various biotechnology companies.

Gilead Sciences has increased its beneficial ownership in Assembly Biosciences to 25.1% following a recent public offering.

Gilead Sciences has finalized its acquisition of Arcellx, Inc. following a successful tender offer and subsequent merger, making Arcellx a wholly owned subsidiary.

Gilead Sciences, Inc. announces a definitive agreement to acquire Arcellx, Inc. for approximately $8.1 billion, including a contingent value right, following a tender offer.

Gilead Sciences, Inc. has filed an Amendment No. 6 to Schedule 13D, updating its beneficial ownership in Arcus Biosciences, Inc. to 25.6% of outstanding common stock.

Gilead Sciences, Inc. increased its beneficial ownership in Assembly Biosciences, Inc. to 29% through a $45 million purchase of common stock and warrants.

Gilead Sciences, Inc.'s option to acquire additional shares in Arcus Biosciences, Inc., potentially increasing its stake to 35%, expired on July 13, 2025, leaving its beneficial ownership at 29.7%.

Vanguard Capital Management has filed a Schedule 13G reporting a 7.51% beneficial ownership stake in Gilead Sciences Inc.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting 0% beneficial ownership in Gilead Sciences Inc. following an internal realignment.

Gilead Sciences, Inc. has increased its beneficial ownership in Xilio Therapeutics, Inc. to 19.9% through a series of share issuances and pre-funded warrants.

Gilead Sciences, Inc. has reported a complete divestment of its beneficial ownership in Cypherpunk Technologies Inc., holding 0% of common stock.

FMR LLC and Abigail P. Johnson have disclosed a 5.3% beneficial ownership stake in Gilead Sciences Inc. common stock.

Gilead Sciences, Inc. has increased its beneficial ownership in Xilio Therapeutics, Inc. to 19.9% of common stock, holding over 10.6 million shares.